Drug Research
GSK and Alector to develop antibodies for neurodegenerative diseases
GlaxoSmithKline plc and Alector announced a strategic global collaboration for the development and commercialisation of two clinical-stage, potential first-in-class monoclonal antibodies (AL001 and AL101) designed to elevate progranulin (PGRN) levels. PGRN is a key regulator of immune activity in...
News
Sosei Heptares and InveniAI Enter a Multi-target AI-powered and GPCR-focused Drug Discovery Collaboration
Sosei Group Corporation, the world leader in GPCR-focused structure-based drug design and development, and InveniAI® LLC, a global leader in pioneering the application of artificial intelligence (AI) and machine learning (ML) to transform innovation across drug discovery and development,...
News
Fujifilm to invest additional $850m in FDB to expand capacity for biologics
Fujifilm has unveiled its plans to invest JPY90bn ($850m) in its subsidiary Fujifilm Diosynth Biotechnologies (FDB) to expand its capacity for biologics.
FDB is a Contract Development and Manufacturing Organisation (CDMO) that develops and manufactures recombinant proteins, vaccines, monoclonal antibodies,...
News
Waters to Help Accelerate Biologics Production Through Research Collaboration With Singapores Bioprocessing Technology Institute
Waters Corporation announced an expansion of its joint work with the Bioprocessing Technology Institute (BTI), a research institute of Singapore's Agency for Science, Technology and Research (A*STAR). Among their new collaborative projects, Waters and BTI have started work on...
Clinical Trials
Positive New Data for Johnson & Johnson Single-Shot COVID-19 Vaccine on Activity Against Delta Variant and Long-lasting Durability of Response
Johnson & Johnson announced data that demonstrated its single-shot COVID-19 vaccine generated strong, persistent activity against the rapidly spreading Delta variant and other highly prevalent SARS-CoV-2 viral variants. In addition, the data showed that the durability of the immune...
News
Charles River Laboratories Completes Acquisition of Vigene Biosciences
Charles River Laboratories International, Inc. announced that it has completed the previously announced acquisition of Vigene Biosciences, Inc. for $292.5 million in cash, subject to customary closing adjustments. In addition to the initial purchase price, the transaction includes additional...
News
Clover Announces Advance Purchase Agreement with Gavi for Over 400 Million Doses of Clover’s COVID-19 Vaccine for the COVAX Facility
Clover Biopharmaceuticals (Clover), a global clinical-stage biotechnology company developing novel vaccines and biologic therapeutic candidates to address the world's most life-threatening diseases and public health threats, announced an advance purchase agreement (APA) with Gavi, the Vaccine Alliance, to provide...
Subscribe
- Never miss a story with notifications
- Gain full access to our premium content
- Browse free from any location or device.
Must read